Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)

Next Previous
Trial Profile

Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asfotase alfa (Primary) ; Asfotase alfa (Primary)
  • Indications Hypophosphatasia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals

Most Recent Events

  • 18 Mar 2019 Pooled results from this and five other studies were presented at the 101st Annual Meeting of the Endocrine Society.
  • 20 Mar 2018 Primary endpoint (Long-term Efficacy of Asfotase Alfa in Treating Rickets in Infants and Young Children With Hypophosphatasia (HPP) has been met, according to results presented at The 100th Annual Meeting of the Endocrine Society.
  • 20 Mar 2018 Results (n=10) of final 7 years data from the extension study assessing long term safety and efficacy of asfotase alfa in infants and young children with infantile onset hypophosphatasia (HPP) who completed the ENB002-08 study, were presented at The 100th Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top